The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Poherdy pertuzumab-dpzb Biosimilar | Shanghai Henlius Biotech | 🇺🇸 US 2025-11-13 | Order → | |
| Kygevvi doxecitine, doxribtimine New molecular entityPriority review | Ucb Inc | 🇺🇸 US 2025-11-03 | Order → | |
| Denosumab-Dssb denosumab-dssb Biosimilar | Samsung Bioepis Co Ltd | 🇺🇸 US 2025-10-29 | Order → | |
| Osvyrti denosumab-desu Biosimilar | Accord Biopharma Inc. | 🇺🇸 US 2025-10-29 | Order → | |
| Carbon Dioxide, Usp carbon dioxide | Roberts Oxygen Co Inc | 🇺🇸 US 2025-10-25 | Order → | |
| Lynkuet elinzanetant New molecular entity | Bayer Hlthcare | 🇺🇸 US 2025-10-24 | Order → | |
| Rocuronium Bromide rocuronium bromide New formulation or manufacturer | B Braun Medical | 🇺🇸 US 2025-10-24 | Order → | |
| Blenrep belantamab mafodotin-blmf New biologic | Glaxosmithkline Llc | 🇺🇸 US 2025-10-23 | Order → | |
| Dehydrated Alcohol dehydrated alcohol New formulation or manufacturer | Be Pharms | 🇺🇸 US 2025-10-23 | Order → | |
| Javadin clonidine hydrochloride New dosage form | Azurity | 🇺🇸 US 2025-10-23 | Order → | |
| Contepo fosfomycin disodium New active ingredientPriority review | Meitheal | 🇺🇸 US 2025-10-22 | Order → | |
| Epioxa Hd/Epioxa Kit riboflavin 5'-phosphate sodium New formulation or manufacturer | Glaukos | 🇺🇸 US 2025-10-17 | Order → | |
| Winlevi clascoterone Additional monitoring | Cassiopea S.p.A. | Acne Vulgaris | 🇪🇺 EU 2025-10-17 | Order → |
| Ferabright ferumoxytol New indication (separate NDA) | Azurity | 🇺🇸 US 2025-10-16 | Order → | |
| BLA761495 New biologicPriority review | Merck Sharp And Dohme Llc | 🇺🇸 US 2025-10-15 | Order → | |
| Jascayd nerandomilast New molecular entityPriority review | Boehringer Ingelheim | 🇺🇸 US 2025-10-07 | Order → | |
| Lasix Onyu furosemide New dosage form | Sq Innovation | 🇺🇸 US 2025-10-07 | Order → | |
| Eydenzelt aflibercept-boav Biosimilar | Celltrion Inc | 🇺🇸 US 2025-10-02 | Order → | |
| Rhapsido remibrutinib New molecular entityPriority review | Novartis | 🇺🇸 US 2025-09-30 | Order → | |
| Clotic clotrimazole New dosage formPriority review | Carwin Pharm Assoc | 🇺🇸 US 2025-09-26 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.